VYNE Therapeutics Amends Merger Agreement with Yarrow Bioscience, Introduces Pre-Funded Warrants

summarizeSummary

VYNE Therapeutics Inc. amended its December 2025 merger agreement with Yarrow Bioscience, introducing pre-funded warrants to manage beneficial ownership limits for Yarrow shareholders and clarifying pre-closing dividend distribution.

check_boxKey Events

• Amendment to Merger Agreement

  VYNE Therapeutics Inc. entered into an amendment to its Agreement and Plan of Merger and Reorganization with Yarrow Bioscience, Inc., originally dated December 17, 2025.

• Introduction of Pre-Funded Warrants

  The amendment provides for the issuance of pre-funded warrants to Yarrow capital stock holders if their share entitlement from the merger exceeds a beneficial ownership limitation (default 9.99%, up to 19.99%). These warrants allow the purchase of VYNE common stock at a nominal exercise price ($0.0001) for the excess shares.

• Clarification of Parent Pre-Closing Dividend

  The amendment clarifies that the Parent Pre-Closing Dividend may be awarded to holders of both outstanding VYNE Common Stock and shares underlying certain outstanding Parent Warrants.

auto_awesomeAnalysis

VYNE Therapeutics Inc. has filed an amendment to its previously announced merger agreement with Yarrow Bioscience, Inc. This amendment introduces a mechanism for issuing pre-funded warrants to Yarrow shareholders to manage beneficial ownership limitations, ensuring compliance while facilitating the merger. Additionally, it clarifies the distribution of the Parent Pre-Closing Dividend to include holders of existing Parent Warrants. These adjustments are material to the structure and execution of the merger, providing necessary operational details for a significant corporate transaction.